Could Avexis Inc (NASDAQ:AVXS) See a Reversal After Less Sellers Came In?

June 19, 2018 - By Migdalia James

The stock of Avexis Inc (NASDAQ:AVXS) registered a decrease of 1.59% in short interest. AVXS’s total short interest was 2.99M shares in June as published by FINRA. Its down 1.59% from 3.04M shares, reported previously. With 1.04M shares average volume, it will take short sellers 3 days to cover their AVXS’s short positions. The short interest to Avexis Inc’s float is 11.36%.

The stock increased 0.08% or $0.18 during the last trading session, reaching $217.83. About 613,648 shares traded. AveXis, Inc. (NASDAQ:AVXS) has 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $8.02 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

AveXis, Inc. (NASDAQ:AVXS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.